MDxHealth Suspends Full-Year 2026 Revenue Guidance
MDxHealth suspended its full-year 2026 revenue guidance. The company also announced preliminary third-quarter revenue, but the available text provides no figure.
Story updates
08:01:22 PM UTC
SquawkNews
MDxHealth: Suspends Full-Yr 2026 Rev Guidance of $110M-$115M >MDXH
08:01:24 PM UTC
SquawkNews
MDxHealth Suspends FY2026 Revenue Guidance Of $110M-$115M; Reports Preliminary Q3 Revenue Of About $22.7M vs. $22.7M Year Ago
08:01:52 PM UTC
SquawkNews
MDxHealth SA suspended its 2026 revenue guidance of $110—115M and expects preliminary unaudited Q3 2026 revenue of about $22.7M, flat vs Q3 2025. Cash was ~$31.7M at Sept. 30, 2026.Material DetailsContext by AI AnalystThis is a mid-cycle setback as the company integrates acquisitions and shifts its…
08:18:57 PM UTC
SquawkNews
By Connor HartMDxHealth suspended its full-year outlook, after preliminary revenue fell short of the company's expectations during the latest quarter.The company said Thursday it expects to report third-quarter revenue from continuing operations of about $22.7 million, missing the $28.8 million tha…
IRVINE, CA — October 15, 2026 — MDxHealth SA NASDAQ:MDXH (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced preliminary unaudited revenue from continuing operations for the third quarter ended September 30, 2026, and suspends its full…